Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
Eur J Neurol
; 31(3): e16164, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38015467
3.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
4.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Cancer
; 129(14): 2179-2191, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021929
5.
Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy.
Am J Ther
; 30(5): e447-e453, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37713689
6.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
7.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
8.
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.
Biol Blood Marrow Transplant
; 26(1): 44-49, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31518644
9.
Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma.
Haematologica
; 108(12): 3477-3479, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439332
10.
Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Future Oncol
; 11(12): 1729-39, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26075441
11.
Daratumumab proves safe and highly effective in AL amyloidosis.
Br J Haematol
; 185(2): 342-344, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938774
12.
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood Cancer J
; 14(1): 69, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649340
13.
Extensive Intracardiac Cement Embolism in a Patient Undergoing Workup for Bone Marrow Transplant.
J Hematol
; 12(6): 283-286, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38188473
14.
Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 23(2): e85-e96, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411211
15.
Outcomes After Salvage Autologous Hematopoietic Cell Transplant for Patients With Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience.
Clin Lymphoma Myeloma Leuk
; 23(3): e182-e189, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36581554
16.
Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma.
Leuk Lymphoma
; 64(7): 1315-1321, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199099
17.
Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma.
Front Oncol
; 13: 1216461, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37554170
18.
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Transplant Cell Ther
; 29(3): 174.e1-174.e10, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36494017
19.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Lancet Haematol
; 10(10): e825-e837, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708911
20.
Multidisciplinary Approach to Older Adults with Hematologic Malignancies-a Paradigm Shift.
Curr Hematol Malig Rep
; 17(1): 31-38, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35028826